THE EMERGENCE OF ANTIBIOTIC RESISTANT MICROORGANISMS (ARMS) HAS CONTINUED TO LIMIT THE EFFECTIVENESS OF ANTIBIOTIC THERAPY OF INFECTED HUMANS AND ANIMALS. DESPITE THE GROWING NEGATIVE IMPACT OF ANTIMICROBIAL RESISTANCE (AR) ON PUBLIC AND ANIMAL HEALTH THERE ARE A FEW EFFECTIVE STRATEGIES FOR REDUCING THEIR PREVALENCE IN FARM ANIMALS. IN THIS STUDY WE PROPOSE TO DEVELOP AN INTEGRATED TECHNOLOGY TO MITIGATE THE PROBLEMS CASED BY ARMS. WE WILL 1) DEVELOP INNOVATIVE APPLICABLE NANO SIZE ANTIMICROBIALS BY COMBINING CHITOSAN NANOPARTICLES ANTIBIOTICS AND &BETA;-LACTAMASE (AN ENZYME THAT BREAK DOWN ANTIBITOTICS) INHIBITORS (CNAI) 2) ELUCIDATE MECHANISMS OF ANTIMICROBIAL ACTIVITY DRUG DELEVERY/RELEASE AND POTENTIAL SIDE EFFECTS AND 3) EVALUATE EFFICACY OF DEVELOPED ANTIMICROBIALS IN DAIRY COWS INFECTED WITH MULTI-DRUG RESISTANT BACTERIA TO TREAT METRITIS DISEASE. METRITIS IS AN ACUTE INFLAMMATORY DISEASE OF THE UTERINE LINING CAUSED BY MICROBIAL INFECTION WITH SYSTEMIC IMPLICATIONS THAT AFFECTS 20 TO 40% OF DAIRY COWS AFTER CALVING. THE DIRECT ECONOMIC COST TO THE US DAIRY INDUSTRY ASSOCIATED WITH METRITIS IS APPROXIMATELY $600 MILLION ANNUALLY. THIS PROPOSED WORK IS INNOVATIVE AND SIGNIFICANT BECAUSE OUTCOMES OF THIS PROJECT ARE EXPECTED TO LEAD TO PRACTICAL EFFECTIVE NEW TREATMENT OPTIONS USING NANOTECHNOLOGY. OVERALL WE EXPECT THAT THE DEVELOPMENT OF THE NEW HIGH VALUE-ADDED NANO-ANTIMICROBIALS WILL HELP IMPROVE ANIMAL AND HUMAN HEALTH. FURTHERMORE THE STUDY WILL BE A FRAMEWORK TO TREAT INFECTIONS CAUSED BY MULTI-DRUG RESISTANT PATHOGENS ON PUBLIC AND ANIMAL HEALTH.